CD1-MR1 2025
Chairs: Giulia Casorati & Masaki Terabe
Sponsored by:
Arovella Therapeutics
Adoptive immunotherapy of metastatic colon cancer with tumor redirected iNKT cells (#67)
2:45 PM
iNKT cells: versatile platforms for direct and recombinant antigen receptor-mediated cancer therapies alone and in rational immunotherapy combinations (#68)
3:05 PM
Development of CAR-iNKT cells for the treatment and haematological malignancies and solid tumours (#187)
3:20 PM